Resistell, a leader in phenotypic nanomotion technology for measuring living cells, is proud to announce the launch of its next international, multisite clinical study, PHENOTECH-1.
The study will be conducted in Switzerland (Lausanne), Spain (Madrid), and Austria (Innsbruck) and is aimed at assessing the sensitivity, specificity, accuracy and time to result of the Resistell Phenotech device in testing the antibiotic susceptibility of Gram-negative bacteria, including E. coli and K. pneumoniae, to clinically relevant antibiotics.
The study, which is designed as a prospective, non-interventional, multicenter, single-arm study, will provide crucial information for healthcare providers in their decision-making process for the treatment of patients with difficult-to-treat infections.
Resistell is thrilled to announce that site initiation visits in three hospitals involved have taken place and that the first patients have already been recruited for the study. The company would like to extend its gratitude to its clinical partners in Switzerland, Spain, and Austria for participating in this exciting journey.
“I am extremely excited to see the study up and running. I believe that the data we will collect will provide further proof that our unique nanomotion technology can help save lives and directly tackle one of the world’s largest unmet medical needs.” said the Co-founder and CEO of Resistell, Danuta Cichocka.